The Shenzhen Stock Exchange will begin delisting Changsheng Bio-Technology on Friday. The vaccine-maker engaged in “major illegal activities” and violated “public health and safety” when it fabricated data for a rabies vaccines that was given to infants, the exchange said.

The company is the latest target of regulators’ campaign to cleanse bad stocks that blight China’s $7 trillion equity market. Changsheng is set to become the first firm ensnared by new delisting rules published on Nov. 16, and the move is likely to trigger a slew of similar cases involving fraud and other violations. The delisting will also impact thousands of Changsheng investors who still own its stock.